As is shown in Figure 7, the expression levels of NRG2 and NRG3 in LGG, and NRG4 in GBM are significantly associated with neoantigen counts, indicating that NRGs may contribute to the clinical immunotherapy. Here, NRG2 is linked to glioblastoma.